Skip to main content
OpenTrials
Completed

NCT Number: NCT07121933

Evaluation of Erchonia PPL Laser as a Pretreatment Adjunct to Enhance Standard Erchonia Red Laser for the Relief of Pain

This study is to see if applying pre-treatment with the Erchonia® PPL blue laser therapy, followed sequentially with the standard Erchonia red laser therapy can help reduce nociceptive musculoskeletal pain

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Primary location

Laser Chiropractic

West Covina, California, 91790, United States

About this study

It is the goal of this single (active) group study to evaluate the efficacy of the pre-treatment with the Erchonia® PPL blue laser therapy, followed sequentially with the standard Erchonia red laser therapy, is non-inferior to (equivalent to or superior to) the standard Erchonia red laser therapy when applied alone in providing temporary relief of nociceptive musculoskeletal pain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 22 years of age or older
  • Primary language is English
  • Subject presents with with one or more of:
  • chronic neck pain on the right side of the neck and/or the left side of the neck and/or the back of the neck; and/or
  • chronic shoulder pain on the right shoulder and/or the left shoulder.
  • Subject is diagnosed with of one or more of the following:
  • Osteoarthritis: Degenerative Joint Disorder (DJD)
  • Chronic Muscle Spasms
  • Cervical and Thoracic Spine Sprain Strain
  • Pain is chronic, having persisted for longer than the past 30 days
  • Self-reported Pain rating on the 0-100 Visual Analog Scale (VAS) of 50 or greater.
  • Willing and able to refrain from consuming any over-the-counter and/or prescription medication(s) and/or herbal supplements intended for the relief of pain and/or inflammation, including muscle relaxants throughout the course of study participation.
  • Willing and able to refrain from engaging in any non-study procedure therapies throughout the course of study participation, including conventional therapies such as physical therapy, occupational therapy and hot or cold packs, as well as alternative therapies such as chiropractic care and acupuncture

Exclusion criteria

  • Presenting primary pain is located outside or in addition to the region of the neck (right side/left side/back) or the shoulder (right and/or left side)
  • Etiology of neck/shoulder pain cannot be definitively diagnosed; or has bene diagnosed as being in whole or in part other than that of osteoarthritis, chronic muscle spasms or cervical and thoracic spine sprain strain; or other potentially contributing etiologies cannot be satisfactorily ruled out
  • Pain is acute: symptoms prevailed for fewer than each of the prior 30 days
  • Current active chronic pain disease: such as chronic fatigue syndrome and fibromyalgia
  • Use of analgesics or muscle relaxants within 7 days prior to study procedure administration
  • Use of systemic corticosteroid therapy (inhaled and topical corticosteroids permitted), narcotics or Botulinum toxin (Botox®) injection in the neck / shoulder region within 30 days prior to study procedure administration
  • Active cancer or treatment for cancer within the last 6 months
  • Unstable cardiac disease, such as recent cardiac arrhythmia, congestive heart failure or myocardial infarction
  • Prior surgery to the neck/shoulder region
  • Known herniated disc injury
  • Active infection, would or other external trauma to the areas to be treated with the laser
  • Medical, physical, or other contraindications for or sensitivity to light therapy
  • Serious known mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years
  • Pregnant or breast feeding
  • Participation in a research study within the past 30 days

Treatment and study plan

Erchonia® PPL blue laser therapy, followed sequentially with the standard Erchonia red laser therapy

Device

450 nanometers (nm) blue dual-diode laser application followed by 640nm red laser application

Primary outcomes

  1. Percentage of Subjects With 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS)

    Time frame: Day 1

    The Visual Analog Scale (VAS) from one day, baseline to endpoint measurement (following 13-minute treatment administration) is calculated for each subject. Individual subject success is defined as a 30% or greater change in VAS pain scores across the evaluation period. A negative (-) percent change indicates a decrease in pain level and is positive for individual subject success. A positive (+) percent change indicates an increase in pain level and is negative for individual subject success.

    Overall study success criteria is defined as at least 65%±5% (percentage of subjects) meeting the study individual success criteria.

Sponsors and collaborators

Lead sponsor

Erchonia Corporation

Industry

Registry information

Official study title

An Evaluation of The Erchonia® PPL Laser as a Pre-Treatment Adjunct to Enhance Standard Erchonia Red Laser Therapy for the Temporary Relief of Nociceptive Musculoskeletal Pain

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 14, 2025
Registry last updated
Jun 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.